Author

Y. Weisblum

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 4 Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 12 Organism:human· 11 Assay:proteomics· 8 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

F. Schmidt· 11 shared T. Hatziioannou· 11 shared F. Muecksch· 10 shared P. D. Bieniasz· 10 shared C. Gaebler· 9 shared M. Caskey· 9 shared M. C. Nussenzweig· 8 shared A. Cho· 6 shared

Activity by Year

2020-2021 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersMicrobiology

F. Schmidt

Mutual co-authors in cluster

Author profile →

13 papers

Recent·Most cited

VPS29 exerts opposing effects on endocytic viral entry

D. Poston, Y. Weisblum, A. Hobbs, P. D. Bieniasz

The paper identifies VPS29 as a host factor that influences viral entry by modulating endosome properties, with opposing effects on coronavirus and influenza virus infections.

bioRxiv · Aug 6, 2021Microbiology

High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies

F. Schmidt, Y. Weisblum, M. Rutkowska, D. Poston, J. Da Silva, F. Zhang, E. Bednarski, A. Cho, D. Schaefer-Babajew, C. Gaebler, M. Caskey, M. C. Nussenzweig, T. Hatziioannou, P. D. Bieniasz

This study shows that multiple neutralizing epitopes in SARS-CoV-2 spike proteins are targeted by polyclonal antibodies, and 20 mutations can confer resistance, but vaccinated and infected individuals' plasma neutralizes these resistant variants and diverse sarbecoviruses.

bioRxiv · Aug 6, 2021Microbiology

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2

F. D. Mast, P. C. Fridy, N. E. Ketaren, J. Wang, E. Y. Jacobs, J. P. Olivier, T. Sanyal, K. R. Molloy, F. Schmidt, M. Rutkowska, Y. Weisblum, L. M. Rich, E. R. Vanderwall, N. Dambrauskas, V. Vigdorovich, , M. P. Rout

This paper presents a large repertoire of high-affinity nanobodies against SARS-CoV-2 Spike protein with potent neutralization properties and resistance to viral variants.

bioRxiv · Apr 8, 2021Biochemistry

Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry

E. R. Kastenhuber, J. A. Jaimes, J. L. Johnson, M. Mercadante, F. Muecksch, Y. Weisblum, Y. Bram, R. E. Schwartz, G. R. Whittaker, L. C. Cantley

This study shows coagulation factors like factor Xa and thrombin directly cleave SARS-CoV-2 spike, enhancing viral entry, and suggests anticoagulation could reduce infection.

bioRxiv · Mar 31, 2021Microbiology

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies

A. J. Greaney, T. N. Starr, C. O. Barnes, Y. Weisblum, F. Schmidt, M. Caskey, C. Gaebler, M. Agudelo, S. Finkin, Z. Wang, D. Poston, F. Muecksch, T. Hatziioannou, P. D. Bieniasz, D. F. Robbiani, , J. D. Bloom

The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.

bioRxiv · Mar 17, 2021Microbiology

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

bioRxiv · Mar 7, 2021 · PreprintMicrobiology

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Nature · Feb 10, 2021Peer-reviewedImmunology

Evolution of Antibody Immunity to SARS-CoV-2

C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

bioRxiv · Nov 3, 2020Immunology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

bioRxiv · Jun 8, 2020Microbiology

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

C. O. Barnes, A. P. West, K. Huey-Tubman, M. A. G. Hoffmann, N. G. Sharaf, P. R. Hoffman, N. Koranda, H. B. Gristick, C. Gaebler, F. Muecksch, J. C. Cetrulo Lorenzi, S. Finkin, T. Hagglof, A. Hurley, K. G. Millard, , P. J. Bjorkman

bioRxiv · May 28, 2020Immunology

Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity

I. Lui, X. X. Zhou, S. A. Lim, S. Elledge, P. Solomon, N. J. Rettko, B. S. Zha, L. L. Kirkemo, J. A. Gramespacher, J. Liu, F. Muecksch, J. C. C. Lorenzi, F. Schmidt, Y. Weisblum, D. F. Robbiani, , J. A. Wells

This study investigates the interaction between SARS-CoV-2 Spike and ACE2, showing that dimeric ACE2 binds with high affinity to Spike and blocks viral entry, with limited intra-Spike avidity.

bioRxiv · May 21, 2020 · PreprintBiochemistry

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology